|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cardiovascular physiology in the older adults显示文摘 | Xuming Dai Scott L Hummel Jorge B Salazar George E Taffet Susan Zieman Janice B Schwartz | 2015 | Journal of Geriatric Cardiology2015，12，3： | 2 |
| 2 | Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial显示文摘 | David W Andrews Charles B Scott Paul W Sperduto Adam E Flanders Laurie E Gaspar Michael C Schell Maria Werner-Wasik William Demas Janice Ryu Jean-Paul Bahary Luis Souhami Marvin Rotman Minesh P Mehta Walter J Curran | 2004 | The Lancet . 2004 (9422)2004，，9422： | 2 |
| 3 | Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db / db Mice显示文摘 | Hong Chen Olga Charlat Louis A Tartaglia Elizabeth A Woolf Xun Weng Stephen J Ellis Nathan D Lakey Janice Culpepper Karen J More Roger E Breitbart Geoffrey M Duyk Robert I Tepper Jay P Morgenstern | 1996 | Cell1996，，3： | 2 |
| 4 | 风险沟通概要显示文摘1 引言
全球制药公司和卫生当局共同的首要目标即保护患者的用药安全。为了实现这一目标,制药公司和卫生当局不断寻求更新、更好的方式,以确保药品正确用于适用人群,并最大限度降低药品不良反应发生的风险。药物警戒不仅加强了传统的回顾性监测,即对从产品研发期间到上市后发生的不良事件做出反应,也增加了前瞻性职能(即试图预测用药风险并避免其发生)。上述监测中,须制定计划以解决从信息中获取到的问题。该计划通常应包括如何采取有效途径将药品的新的风险传达给潜在的广泛人群。 | Carrie E Corboy Janice K Bush 无 | 2009 | 中国药物警戒2009，6，7： | 2 |
| 5 | Biologic and Quality of Life Outcomes From the Mediterranean Life style Pro- gram显示文摘 | Deborah J Janice L Russell E | 2003 | Diabetes Care2003，，26： | 1 |
| 6 | Depressive symptoms and the risk of type 2 diabetes显示文摘 | Sherita Hill Golden Janice E Williams | 2004 | Diabetes Care Alexandria2004，27，42： | 1 |
| 7 | Measurement of DNA copy number at microsatellite loci using quantitative PCR anal-ysis显示文摘 | David G G Tony E G Janice N | 2000 | Cancer Research2000，60，： | 1 |
| 8 | Improving manufacturing performance through process change and knowledge creation 显示文摘 | Janice E C Cheryl G | 2000 | Management Science2000，46，2： | 1 |
| 9 | Improving Manufacturing Performance Through Process Channel and Knowledge Creation 显示文摘 | Carrillo Janice E Gaimon Cheryl | 2000 | Management Science2000，46，： | 1 |
| 10 | High-fiber cereal reduces postprandial insulin responses in hyperinsulinemic but not normoinsulinemic subjects显示文摘 | THOMAS M S JANICE E CAMPBELL | 2004 | Diabetes Care2004，27，： | 1 |
| 11 | Sourcing decisions with stochastic supplier reliability and stochastic demand显示文摘 | Gerald J Janice E Asoo J | 2009 | Production and Operations Management2009，18，4： | 1 |
| 12 | Flowering phenology of six woodyplants in the northern Sonoran Desert显示文摘 | Janice E Bv Mark A D | 1994 | Bulletin of the Torrey Botanical Club1994，121，3： | 1 |
| 13 | Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK)显示文摘 | Christopher S Gray Anthony J Hildreth Peter A Sandercock Janice E O'Connell Donna E Johnston Niall EF Cartlidge John M Bamford Oliver F James K George MM Alberti | 2007 | Lancet Neurology2007，，5： | 1 |
| 14 | Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis 显示文摘 | DAVID G G TONY E G JANICE N | 2000 | Cancer Research2000，60，： | 1 |
| 15 | Employing a transgenic animal model to obtain cementoblasts in vitro显示文摘 | John A D Janice E B Hongjiao Ouyang | 2000 | J Periodontol2000，71，： | 1 |
| 16 | Cementoblast delivery for periodontal tissue engineering显示文摘 | Ming Zhao Qiming Jin Janice E | 2004 | J Periodontol2004，75，1： | 1 |
| 17 | Loss of susceptibility as an alternative for nematode resistance显示文摘 | Janice de Almeida Enger Bruno F Gilbert E | 2005 | Current Opinion in Biotechnology2005，16，2： | 1 |
| 18 | 雷米普利、替米沙坦或二者联用对心血管病高危人群肾脏结局的影响(ONTARGET研究):一项多中心、随机、双盲、对照试验显示文摘背景血管紧张素受体阻断剂(ARB)和血管紧张素转换酶抑制剂(ACEI)都可以减少蛋白尿,二者联用可能比单一用药更有效。目前还没有长期临床试验比较两者对肾功能的影响。本研究比较了雷米普利(一种ACEI)、替米沙坦(一种ARB)或二者联用对患有动脉粥样硬化性血管病或糖尿病合并终末器官损害的人群(年龄≥55岁)肾脏结局的影响。方法临床试验从2001年开始,到2007年结束。经过3周的导入期,25620例受试者被随机分配至10mg/d雷米普利组(n=8576)、80mg/d替米沙坦组(n=8542)或10mg/d雷米普利+80mg/d替米沙坦组(n=8502;中位随访期为56个月),同时检测肾功能和尿蛋白。主要肾脏结局为透析、血清肌酐加倍和死亡的复合终点。采用意向性治疗分析。本研究已在ClinicalTrials.gov注册,编号为NCT00153101。结果试验期间,784例患者因低血压症状提前终止随机治疗(联合用药组406例,雷米普利组149例,替米沙坦组229例)。替米沙坦组和雷米普利组发生复合终点事件的例数相近[替米沙坦组1147例(13.4%),雷米普利组1150例(13.5%);HR1.00(95%C10.92~1.09)],但在联合用药组有所增加[1233例(14.5%);HR1.09(95%CI1.01-1.18),P=0.037]。次要肾脏结局(透析或血清肌酐加倍)的发生例数在替米沙坦组(189例,2.21%)和雷米普利组(174例,2.03%)相近(HR1.09,95%C10.89~1.34),但在联合用药组显著增加(212例,2.49%:HR1.24,95%CI1.01~1.51.P=0.038)。肾小球滤过率估计值在雷米普利组下降最少,为-2.82ml/(min·1.73m^2)(s=17.2),而在替米沙坦组为-4.12ml/(min·1.73m^2)(S=17.4,P〈0.0001),在联合治疗组为-6.11ml/(min·1.73m^2)(S=17.9,P〈0.0001)。与雷米普利组相比,替米沙坦组(P=0.004)和联合用药组(P=0.001)较少发生尿蛋白排泄增加。结论在心血管病高危人群中,替米沙坦和雷米普利对肾脏结局的影响相同。尽管联合用药比单一治疗能更大程度减少蛋白尿,但总体上其增加了肾脏结局事件。基金 勃林格殷格翰公司。 | Johannes F E Mann, Roland E Schmieder Matthew McQueen Leanne Dyal Helmut Schumacher Janice Pogue Xingyu Wang Aldo Maggioni Andrzej Budaj Suphachai Chaithiraphan Kenneth Dickstein Matyas Keltai Kaj Metsarinne Ali Oto Alexander Parkhomenko Leopoldo S Piegas Tage L Svendsen Koon KTeo Salim Yusuf 刘欣(译) 王兴宇(审) | 2009 | 世界临床医学2009，，4： | 1 |
| 19 | Dynamic cytoskeleton rearrangements in giant cells and syncytia of nematode-infected roots显示文摘 | DE A E JANICE V P KRIS K M | 2004 | The Plant Journal2004，38，1： | 1 |
| 20 | Falini, Using environmental insurance to manage risk encountered in non - traditional transaction 显示文摘 | Janice E | 2003 | Villanova Environmental Law Journal2003，，14： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员